CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) and Kyntra Bio (NASDAQ:KYNB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.
Risk and Volatility
CollPlant Biotechnologies has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Earnings and Valuation
This table compares CollPlant Biotechnologies and Kyntra Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CollPlant Biotechnologies | $2.37 million | 3.30 | -$11.49 million | ($13.59) | -0.30 |
| Kyntra Bio | $6.44 million | 2.87 | $183.45 million | $45.30 | 0.10 |
Kyntra Bio has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CollPlant Biotechnologies and Kyntra Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CollPlant Biotechnologies | -678.37% | -298.21% | -167.83% |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for CollPlant Biotechnologies and Kyntra Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
| Kyntra Bio | 2 | 0 | 5 | 0 | 2.43 |
CollPlant Biotechnologies presently has a consensus price target of $120.00, suggesting a potential upside of 2,798.55%. Kyntra Bio has a consensus price target of $36.80, suggesting a potential upside of 705.25%. Given CollPlant Biotechnologies’ higher probable upside, equities analysts clearly believe CollPlant Biotechnologies is more favorable than Kyntra Bio.
Institutional & Insider Ownership
21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Kyntra Bio beats CollPlant Biotechnologies on 10 of the 14 factors compared between the two stocks.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
